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Introduction {#sec1}
============

Energy homeostasis is regulated by neurotransmitters and by humoral factors including thyroid hormones, which act within the hypothalamus and systemically to regulate food intake ([@bib8], [@bib6]) and energy expenditure ([@bib17]). The effects of the active form of thyroid hormone, 3,5,3′-[l]{.smallcaps}-triiodothyronine (T3), are mediated by two thyroid hormone receptors (TRα and TRβ), encoded by *Thra* and *Thrb*, respectively ([@bib5]).

Metabolic phenotypes have been described in mice and humans with TR mutations. Mice with heterozygous dominant-negative mutations of TRα display a variety of metabolic phenotypes ranging from hypermetabolism, hyperphagia, and resistance to diet-induced obesity ([@bib30]) to increased visceral adiposity, hypophagia, and impaired cold-induced adaptive thermogenesis ([@bib19]). The variation in described phenotypes is likely to be due to the differing actions of individual mutant receptors on wild-type TR function ([@bib27]). Humans with heterozygous dominant-negative mutations of TRα (resistance to thyroid hormone α \[RTHα\]) may be overweight or obese with reduced energy expenditure ([@bib3], [@bib25], [@bib26]). Humans with heterozygous dominant-negative mutations of TRβ have RTHβ, resulting in high levels of circulating thyroid hormones and thyroid-stimulating hormone (TSH) due to impaired negative feedback of the hypothalamic-pituitary-thyroid axis ([@bib27]). Humans with RTHβ may be overweight and hyperphagic ([@bib23]) despite features of hyperthyroidism such as tachycardia and raised energy expenditure due to T3 actions in TRα-responsive tissues. These extensive studies demonstrate that thyroid hormone is an essential regulator of food intake and energy expenditure. Despite this, clinical and global gene targeting studies cannot differentiate between the developmental and adult, or systemic and central, effects of thyroid hormones.

The ventromedial hypothalamus (VMH) is a critical region of the brain involved in energy homeostasis. TRβ is the predominant TR isoform expressed in the VMH ([@bib7], [@bib1]), and previous studies suggest that thyroid hormones acting in the VMH regulate both food intake ([@bib18]) and energy expenditure ([@bib20]). Thus, we hypothesize that, in the VMH, TRβ physiologically regulates food intake and body weight. To investigate this hypothesis directly, we used stereotaxic Cre-lox gene targeting to generate a VMH-specific model of TRβ knockdown in adult mice.

Results {#sec2}
=======

Tissue-Specific Knockdown of TRβ in the VMH in Adult Mice {#sec2.1}
---------------------------------------------------------

We knocked down TRβ in the VMH of adult male mice using Cre-mediated excision of a floxed critical exon in the *Thrb* gene. This approach enabled temporally and spatially controlled reduction of TRβ expression specifically in the VMH of adult mice. This model eliminates the developmental consequences and abnormal systemic thyroid hormone levels that occur in global TRβ mutant mice ([@bib27]) or in hypothyroid and thyrotoxic animals ([@bib16], [@bib20]).

The *Thrb*^*flox*^ allele contains loxP sites flanking exon 5 of *Thrb* ([@bib33]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). *Cre-recombinase*-mediated excision of this critical exon results in inactivation of *Thrb* ([@bib33]). *Cre recombinase* was introduced into the VMH of adult male *Thrb*^*flox/flox*^ mice by stereotaxic injection of recombinant adeno-associated virus (rAAV) expressing a Cre-GFP fusion protein to generate mice with reduced TRβ expression in the VMH (VMH-TRβ^−^) mice. *Thrb*^*flox/flox*^ mice injected with rAAV encoding GFP into the VMH (VMH-GFP) were used as controls. Cre-mediated excision of the *Thrb*^flox^ allele was confirmed by PCR of DNA from whole hypothalami of VMH-TRβ^−^ mice ([Figure S1](#mmc1){ref-type="supplementary-material"}B). The *Thrb*^*flox*^ allele was not excised in either the cerebellum or brainstem, indicating rAAV did not enter the ventricular system following stereotaxic injection ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Fluorescence microscopy and in situ hybridization (ISH) both confirmed transgene expression localized to the VMH in both groups of mice ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). ISH using a probe specific for the floxed exon of *Thrb* demonstrated reduced expression within the VMH of VMH-TRβ^−^ mice compared with controls ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D).

Selective Knockdown of TRβ in the VMH in Adult Mice Results in Hyperphagia and Obesity {#sec2.2}
--------------------------------------------------------------------------------------

VMH-TRβ^−^ mice consumed more food and gained more weight than controls ([Figures 1](#fig1){ref-type="fig"}A and 1B). Weight gain in VMH-TRβ^−^ mice was three times greater than that of control mice by the end of the study ([Figures 1](#fig1){ref-type="fig"}C and 1D).Figure 1Effect of Reduced TRβ Expression in the VMH(A) Cumulative food intake.(B) Cumulative body weight change.(C) Body weight on day 42.(D) Photograph of VMH-GFP and VMH-TRβ^−^ mouse.(E) Hypothalamic expression of *Pomc*.(F) Hypothalamic expression of *Npy*.In (A)--(C), the results are mean ± SEM; n = 10 for VMH-GFP and 11 for VMH-TRβ^−^. In (E) and (F), the results are median, and whiskers are minimum and maximum; n = 3 for VMH-GFP and 4 for VMH-TRβ^−^; ^∗^p \< 0.05; ^∗∗^p \< 0.01. Food intake and body weight were analyzed using a generalized estimating equation exchangeable correlation matrix and robust SEs (GEE), body weight data t test. See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

Whole hypothalami for RNA-sequencing (RNA-seq) analysis were collected from mice before significant changes in body weight had occurred. This was so that changes in expression are likely to be due to changes in thyroid hormone signaling rather than secondary effects of the increase in body weight and food intake. Differential expression analysis was performed ([Table S1](#mmc2){ref-type="supplementary-material"}). Pathway analysis of differentially expressed genes revealed an over-representation of genes involved in dopamine, growth hormone, and leptin signaling pathways, as well as genes that are involved in neuronal activity regulation including long-term potentiation (LTP) and long-term depression (LTD); these results were qualitatively the same when the false discovery rate (FDR) for analysis was set between 0.001 and 0.1 ([Table S2](#mmc3){ref-type="supplementary-material"}). Among the genes differentially expressed, *Pomc* expression was decreased (log Fc −1.38, p = 9.33 × 10^−7^) ([Figure 1](#fig1){ref-type="fig"}E), whereas *Npy* expression was increased (log Fc 0.7, p = 9.42 × 10^−6^) ([Figure 1](#fig1){ref-type="fig"}F), whereas that of *Thrb* was not altered at the level of the whole hypothalamus ([Table S1](#mmc2){ref-type="supplementary-material"}). Expression of steroidogenic factor 1 (*Nr5a1*), and uncoupling protein-2 (*Ucp2*), both of which are implicated in hypothalamic control of energy homeostasis ([@bib22], [@bib8]), were unchanged. The differentially expressed genes were compared to those previously reported to be T3 responsive or directly regulated by T3 in cerebrocortical cells ([Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"} and [Figure S3](#mmc1){ref-type="supplementary-material"}) ([@bib13]). Of the genes directly regulated by T3 in cerebrocortical cells, we identified 89 (∼15%) were also significantly changed in our samples, among which was hairless (*Hr*). For genes regulated indirectly by T3, we identified 133 that were also changed (∼9%).

Total, visceral, subcutaneous, and epididymal fat mass were all increased in VMH-TRβ^−^ mice compared to controls ([Figures 2](#fig2){ref-type="fig"}A--2E). In keeping with the increased adiposity, VMH-TRβ^−^ mice had a higher plasma leptin concentration than controls ([Figure 2](#fig2){ref-type="fig"}F).Figure 2White Adipose Tissue Mass and DistributionMRI quantification of fat demonstrated that VMH-TRβ^−^ mice had significantly higher fat mass.(A) Representative transverse T1-weighted MR images through the abdominal region of a VMH-GFP and VMH-TRβ^−^ mouse.(B) Total body fat.(C) Visceral fat.(D) Subcutaneous fat.(E) Epididymal fat pad weight on day 42 (n = 10).(F) Plasma leptin levels on day 42 (n = 10).Results are mean ± SEM (n = 3 per group unless stated). ^∗∗^p \< 0.01 versus control, t test with Bonferroni correction. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

VMH-TRβ^−^ Mice Are Systemically Euthyroid {#sec2.3}
------------------------------------------

Alterations in circulating thyroid hormones affect food intake and body weight ([@bib28]). Measurement of plasma TSH, thyroxine (T4), and T3 confirmed that both VMH-TRβ^−^ and control mice were euthyroid ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C).

VMH-TRβ^−^ Mice Are Insulin Resistant but Do Not Show Changes in the Expression of Genes Involved in Hypothalamic Glucose Sensing {#sec2.4}
---------------------------------------------------------------------------------------------------------------------------------

Obese VMH-TRβ^−^ mice had high levels of fasting insulin ([Figure S4](#mmc1){ref-type="supplementary-material"}D), as expected. However, when glucose tolerance and insulin tolerance were tested before the development of obesity in the VMH-TRβ^−^ mice, there were no differences between the VMH-TRβ^−^ and VMH-GFP mice ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F). RNA-seq analysis did not identify changes in expression of hypothalamic glucose-sensing genes.

Obesity in VMH-TRβ^−^ Mice Is Not Due to TRβ Knockdown in Other Brain Areas {#sec2.5}
---------------------------------------------------------------------------

To confirm that the observed weight gain and hyperphagia in VMH-TRβ^−^ mice resulted from reduced TRβ expression in the VMH and not spread through the ventricular system into other brain regions, rAAV-Cre was injected into both lateral ventricles of *Thrb*^flox/flox^ mice; a control group of mice were injected with rAAV-GFP. There was no difference in cumulative food intake or body weight gain between these two groups ([Figures S4](#mmc1){ref-type="supplementary-material"}G and S4H).

VMH-TRβ^−^ Mice Fail to Mount an Orexigenic Response to Administered T3 {#sec2.6}
-----------------------------------------------------------------------

In order to validate loss of T3 signaling following TRβ inactivation in the VMH, we administered T3 to VMH-TRβ^−^ and VMH-GFP mice by subcutaneous injection. Over the 24-hr study period, T3 significantly increased food intake in VMH-GFP mice but VMH-TRβ^−^ mice failed to mount an orexigenic response to the administered T3 ([Figure S4](#mmc1){ref-type="supplementary-material"}I).

VMH-TRβ^−^ Mice Do Not Become Obese When Pair-Fed to the Food Intake of Lean Controls {#sec2.7}
-------------------------------------------------------------------------------------

To investigate whether the hyperphagia contributed to, or was a consequence of, the development of the obese phenotype, VMH-TRβ^−^ mice were pair-fed to the food intake of a weight-matched VMH-GFP littermate for 5 weeks. During pair-feeding, there was no difference in cumulative body weight change or food intake ([Figures 3](#fig3){ref-type="fig"}A and 3B) or locomotor activity between the two groups.Figure 3Effect of Pair-Feeding on VMH-TRβ^−^ Mice(A) Weight gain over the entire period of the experiment. During weeks 0--5, food intake of each VMH-TRβ^−^ mouse was limited to that of a weight-matched, VMH-GFP littermate. From weeks 5 to 9, ad libitum access to food was restored.(B) Food intake during the pair-feeding period.(C) Food intake during the ad libitum feeding period.Results are mean ± SEM. n = 9; GEE, ^∗^p \< 0.05; ^∗∗∗^p \< 0.001.

After 5 weeks of pair-feeding, ad libitum access to food was restored for 4 weeks. Following restoration of free feeding, VMH-TRβ^−^ mice gained significantly more weight and consumed significantly more food than controls ([Figures 3](#fig3){ref-type="fig"}A and 3C).

VMH-TRβ^−^ Mice Have Reduced Energy Expenditure and Reduced Locomotor Activity {#sec2.8}
------------------------------------------------------------------------------

The contribution of changes in energy expenditure to the obese phenotype was investigated. Oxygen consumption (VO~2~), carbon dioxide production (VCO~2~), and locomotor activity were all decreased during the dark phase in ad libitum-fed VMH-TRβ^−^ mice both before and after the onset of obesity ([Figures 4](#fig4){ref-type="fig"}A--4C). By contrast, there was no difference in VO~2~, VCO~2~, or locomotor activity during the light phase ([Figures 4](#fig4){ref-type="fig"}A--4C). The decrease in nocturnal locomotion in VMH-TRβ^−^ mice was confirmed by behavioral analysis ([Table S3](#mmc1){ref-type="supplementary-material"}). There was no difference in respiratory exchange ratio (RER) ([Figure 4](#fig4){ref-type="fig"}D) and no difference in brown adipose tissue (BAT) uncoupling protein-1 (*Ucp1*) expression ([Figure 4](#fig4){ref-type="fig"}E) between VMH-TRβ^−^ and control mice. In addition, VMH-TRβ^−^ mice have a normal body temperature ([Figure S4](#mmc1){ref-type="supplementary-material"}J).Figure 4Energy Expenditure and Locomotor Activity in Mice with Reduced Expression of TRβ in the VMH(A) Oxygen consumption.(B) Carbon dioxide production.(C) Locomotor activity.(D) RER.(E) *Ucp1* expression in BAT (n = 7 VMH-GFP and 11 VMH-TRβ^−^).L, light phase; D, dark phase; 1, 1 week, and 6, 6 weeks, after recovery. Data are mean ± SEM (n = 5 VMH-GFP; n = 6 VMH-TRβ^−^); ANOVA with Student-Newman-Keuls analysis, ^∗∗^p \< 0.01. See also [Table S3](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

These studies identify hypothalamic TRβ as an important physiological regulator of appetite and body weight. Reduced TRβ expression in the VMH resulted in marked weight gain, comparable to severe forms of monogenic obesity ([@bib32], [@bib34]). The weight gain was a consequence of increased total body fat, and in particular a marked increase in subcutaneous and visceral white adipose tissue, the latter being an important risk factor for cardiovascular disease and diabetes ([@bib24]).

VMH-TRβ^−^ mice ate more than control animals, and pair-feeding studies indicated that hyperphagia contributed directly to the obesity. Thus, VMH-TRβ^−^ mice remained lean when food intake was restricted but rapidly became obese when ad libitum feeding was restored.

Selective TRβ knockdown specifically in the VMH was confirmed by ISH and fluorescence microscopy. Although expression of *Thrb* was not reduced in the RNA-seq analysis, these samples are derived from whole hypothalami, and therefore the decrease in the level in the VMH is likely masked by the expression of *Thrb* throughout the rest of the sample. Indeed, the loss of TRβ function in the VMH was demonstrated by the failure of the expected orexigenic response to administered T3 in VMH-TRβ^−^ mice and further supported by the appropriate changes in genes directly regulated by T3. The possibility of the phenotype arising through virus spread to other CNS areas was excluded by rAAV-Cre injection into the lateral ventricles, which did not result in hyperphagia or obesity.

Previous work in rats has reported the acute orexigenic effect of exogenously administered T3 ([@bib18]). Here, we show the endogenous effect of thyroid hormone action following selective TRβ knockdown. We suggest that our current work describes a local circuit within the VMH that physiologically regulates food intake as distinct from the feeding response to administered pharmacological doses of T3 analogous to the contrasting effects of NPY and PYY.

To investigate the underlying cause of hyperphagia in VMH-TRβ^−^ mice, hypothalamic gene expression patterns were determined by RNA-seq. The expression of *Pomc* and *Fto* were downregulated in the hypothalamus, whereas *Npy* was upregulated. POMC and FTO are thought to inhibit food intake, whereas NPY simulates food intake; therefore, these changes in expression may explain in part the phenotype observed.

Energy expenditure in VMH-TRβ^−^ mice was reduced both before and after the onset of obesity. There was no difference in BAT *Ucp1* expression between VMH-TRβ^−^ and control mice, suggesting that adaptive thermogenesis was unaffected. It is likely that changes in energy expenditure in VMH-TRβ^−^ mice resulted from decreased locomotor activity. The reduced locomotor activity is not a consequence of the obesity because it occurred before differences in body weight. In addition, during pair-feeding studies, the reduction in locomotor activity was lost, possibly due to food-seeking behavior. This is likely to explain why body weight gain did not differ between the two groups before the restoration of ad libitum feeding. The energy expenditure and pair-feeding data indicate that both increased food intake and reduced locomotor activity contribute to obesity in VMH-TRβ^−^ mice.

In contrast to VMH-TRβ^−^ mice, global heterozygous TRβ-knockout mice do not have an obese phenotype ([@bib27]). This may be explained by the peripheral hyperthyroidism of these mice. In addition, the appetite circuits within the hypothalamus are subject to developmental plasticity and compensatory redundancy ([@bib4], [@bib15]). For example, neither global deletion of *Agrp* and/or *Npy* nor ablation of arcuate AgRP/NPY neurons in neonatal mice results in a metabolic phenotype ([@bib9], [@bib29], [@bib21]), whereas ablation of these neurons in adult mice produces profound hypophagia and starvation ([@bib21], [@bib11], [@bib2]). Similar developmental compensation may occur in global TRβ-knockout mice.

Studies using adenovirus-mediated expression of a dominant-negative TR (DN-TR) in the rat VMH have been reported ([@bib20]). Although VMH DN-TR expression did not affect food intake or body weight in euthyroid animals, it prevented weight loss in thyrotoxic rats and resulted in reduced hypothalamic AMP-activated protein kinase (AMPK) expression ([@bib20]). AMPK expression was unchanged in our model. DN-TR interferes with the actions of both TRα and TRβ and exerts a marked repressive effect on gene transcription ([@bib27], [@bib10]). By contrast, VMH-TRβ^−^ mice have only reduced TRβ activity rather than the pathological repression of TR target genes that is present in animals expressing a dominant-negative receptor. This fundamental difference is likely to explain the contrasting phenotypes observed in these two models.

In summary, we have shown that hypothalamic TRβ is an important physiological regulator of energy homeostasis because TRβ knockdown in the VMH results in a phenotype of hyperphagia and severe obesity that is comparable to some of the most extreme forms of monogenic obesity ([@bib32], [@bib34]). Our findings provide insights into the central regulation of energy homeostasis by TRβ that could be a target for anti-obesity therapies.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

*Thrb*^*flox/flox*^ mice ([@bib33]) were genotyped by PCR using specific oligonucleotide primers ([Figure S1](#mmc1){ref-type="supplementary-material"}). Mice were housed in single cages and maintained under a controlled environment (temperature, 21--23°C; 12-h light--dark cycle, lights on at 07:00) with ad libitum access to chow and water (RM1; SDS Diets), except where stated. Male mice that were 8 weeks old at the start of procedures were used in all experiments. All animal studies were approved under the Animals (Scientific Procedures) Act (1986) (Project License Number 70_7229) and approved by the Animal Welfare and Ethical Review Body, Imperial College London, which is signed up to the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.

rAAV Preparation {#sec4.2}
----------------

rAAV was produced ([@bib14]) and isolated ([@bib35]), as previously described.

Confirmation of rAAV Transgene Expression, *Thrb* Excision, and Reduced TRβ Expression in the VMH {#sec4.3}
-------------------------------------------------------------------------------------------------

Excision of the *Thrb*^*flox*^ allele within the hypothalamus was confirmed by PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}). ISH using a probe specific to the excised portion of TRβ was performed to confirm reduced TRβ expression within the VMH ([@bib31]).

Measurement of Energy Expenditure {#sec4.4}
---------------------------------

Metabolic parameters were measured by indirect calorimetry using an open-circuit Oxymax system of the Comprehensive Lab Animal Monitoring System (Columbus Instruments) ([@bib12]).

RNA-Seq Analysis {#sec4.5}
----------------

RNA-seq analysis was performed using hypothalamic RNA from VMH-GFP (n = 3) and VMH-TRβ^−^ (n = 4) mice using next-generation sequencing (NGS) technologies (Imperial BRC Genomics Laboratory, Imperial College London). For further details, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analyses {#sec4.6}
--------------------

Cumulative food intake and body weight data were analyzed using generalized estimating equations with exchangeable correlation matrix and robust SEs. Differences between two groups at individual time points were analyzed by unpaired t tests; for multiple comparisons, a Bonferroni correction was applied. Values from the behavioral study were analyzed using a one-way ANOVA followed by Kruskal-Wallis test. Data from the energy expenditure test were analyzed using a one-way ANOVA followed by a Newman-Keuls test. Plasma thyroid hormones were compared using Mann-Whitney U test. Differences between groups were considered statistically significant at the 95% confidence level (p \< 0.05).
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